highly disperse silica 0.01-0.1, [preferably 0.01-0.5, particularly 0.04,] and

magnesium stearate 0.01-0.1[, preferably 0.01-0.05, particularly 0.03].

IN THE ABSTRACT:

Please replace the originally filed abstract with the attached abstract.

REMARKS

With entry of this amendment, claims 1-6 are pending. Newly enter claims 5 and 6 recite subject matter that has been deleted from claim 4 in order to overcome indefiniteness rejections. No new matter has been added.

Claims 1, 2 and 4 were rejected under 35 USC § 112, second paragraph, as being indefinite. Claims 1 and 2 have been amended in accordance with the Examiner's helpful suggestions. Claim 4 has been amended to remove preferred ratios, which are now recited in claims 5 and 6. Reconsideration and withdrawal of the rejection is respectfully requested.

Claims 1-4 were rejected under 35 USC § 102(e) as being anticipated by Battistini et al. (USP 5,905,149). This rejection is traversed for the following reasons.

Battistini et al. are concerned with a new class of tyrosine kinase inhibitors. Cyclophosphamide is mentioned only as part of a hypothetical combination. No examples are provided of tablets containing cyclophosphamide, nor is there any teaching that would suggest the presently claimed invention, a film-coated tablet with cyclophosphamide as active compound, comprising in the core cyclophosphamide, one or more fillers, flow regulators, lubricants, and one or more dry binders but no preswollen starch. The cornstarch described in Example 17 of Battistini et al. is a preswollen corn starch: "corn starch (10g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder" (col. 18, lines 47-49). Thus, the teaching of Battistini leads away from the present invention. For these

reasons, it is respectfully submitted that the present invention is not anticipated by Battistini et al. Reconsideration and withdrawal of the rejection are respectfully requested.

Claims 1-4 were rejected under 35 USC § 103 as being unpatentable over Battistini et al. in view of Eugster et al. (USP 5,593,691). This rejection is traversed for the following reasons.

Eugster et al. teach new biotenside esters for use in the preparation of spontaneously dispersible concentrates containing therapeutic or cosmetically active substances (col. 1, lines 7-10). Thus, Eugster et al. do not disclose solid compositions at all. Consequently, it is respectfully submitted that Eugster et al. does not remedy the deficiency of Barristini et al. to teach the present invention. Reconsideration and withdrawal of the rejection are respectfully requested.

Claims 1-4 were rejected under 35 USC § 103 as being unpatentable over Feige et al. (USP 5,229,405) in view of Hoy et al. (USP 5,208,030). This rejection is traversed for the following reasons.

Fiege et al. teach 2-iminothiazolidin-4-one as a novel pharmaceutical agent. Cyclophosphamide is only referenced in the context of its antiarthritic activity (col. 5, lines 28-29). In addition, Feige et al only describe the use of "starch pastes", which are identical to preswollen starch (col. 8, line 9). Thus, it is respectfully submitted that Feige et al. teach away from the present invention.

Hoy et al. teach a dosage device for pesticides. Hoy et al describe neither cyclophosphamide nor nonpreswollen starch (only a special "soluble starch" is mentioned in col. 2, line 59). Thus, Hoy et al. do not remedy the deficiencies of Fiege et al. to teach the present invention. Reconsideration and withdrawal of the rejection are respectfully requested.

All objections and rejections having been addressed, it is respectfully submitted that the application is in condition for allowance, and Notice to that effect is respectfully requested.

Respectfully submitted,

PILLSBURY MADISON & SUTRO LLP

By _____

Ann S. Hobbs, Ph.D.
Registration No. 36,830
Tel. No.: (202) 861-3063
Fax No.: (202) 822-0944

1100 New York Avenue, N.W.
Ninth Floor
Washington, D.C. 20005
(202) 861-3000